---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-226878"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:06:35.245561+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Metagenomi enters LNP license with Acuitas, terminates Affini-T TCR deal

## Summary
- Non-exclusive Acuitas license for LNP technology; low-seven-figure annual maintenance fee until first Phase 1 dosing.
- Milestone payments low to mid seven figures for regulatory/commercial events; royalties low mid-single digit % of net sales.
- Terminated Affini-T agreement effective Sept 30, 2025 due to Affini-T's assignment for benefit of creditors.
- Metagenomi regains full control over IP and rights to develop TCR-based therapeutics previously licensed to Affini-T.
- No future payments expected from Affini-T under terminated agreement.

## SEC filing metadata
- accession: 0001193125-25-226878
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/0001193125-25-226878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/mgx-20250929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-226878
- JSON: https://secwatch.observer/filing/0001193125-25-226878.json
- Plain text: https://secwatch.observer/filing/0001193125-25-226878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.